Wedbush Maintains Neutral on Fate Therapeutics, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has maintained a Neutral rating on Fate Therapeutics (NASDAQ:FATE) and increased the price target from $3 to $7.
February 27, 2024 | 1:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst David Nierengarten maintains a Neutral rating on Fate Therapeutics but raises the price target from $3 to $7.
The increase in price target from $3 to $7 by a reputable analyst suggests a positive outlook on the stock's value, potentially leading to increased investor interest and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100